BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cuevas-Ocaña S, Laselva O, Avolio J, Nenna R. The era of CFTR modulators: improvements made and remaining challenges. Breathe (Sheff) 2020;16:200016. [PMID: 33304402 DOI: 10.1183/20734735.0016-2020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Valamparampil JJ, Gupte GL. Cystic fibrosis associated liver disease in children. World J Hepatol 2021; 13(11): 1727-1742 [PMID: 34904041 DOI: 10.4254/wjh.v13.i11.1727] [Reference Citation Analysis]
2 Bass R, Brownell JN, Stallings VA. The Impact of Highly Effective CFTR Modulators on Growth and Nutrition Status. Nutrients 2021;13:2907. [PMID: 34578785 DOI: 10.3390/nu13092907] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Shemie G, Nguyen MT, Wallenburg J, Ratjen F, Knoppers BM. The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada. J Pers Med 2021;11:382. [PMID: 34067090 DOI: 10.3390/jpm11050382] [Reference Citation Analysis]
4 Forno E, Abman SH, Singh J, Robbins ME, Selvadurai H, Schumacker PT, Robinson PD. Update in Pediatrics 2020. Am J Respir Crit Care Med 2021;204:274-84. [PMID: 34126039 DOI: 10.1164/rccm.202103-0605UP] [Reference Citation Analysis]
5 Laselva O, Ardelean MC, Bear CE. Phenotyping Rare CFTR Mutations Reveal Functional Expression Defects Restored by TRIKAFTATM. J Pers Med 2021;11:301. [PMID: 33920764 DOI: 10.3390/jpm11040301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Laselva O, Qureshi Z, Zeng ZW, Petrotchenko EV, Ramjeesingh M, Hamilton CM, Huan LJ, Borchers CH, Pomès R, Young R, Bear CE. Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator. iScience 2021;24:102542. [PMID: 34142049 DOI: 10.1016/j.isci.2021.102542] [Reference Citation Analysis]